AGP Executive Report
Last update: 4 hours agoHypertension Care Update: Macau’s Health Bureau says 89% of registered hypertension patients are receiving treatment, with 62.6% reaching control—alongside 337 blood-pressure measurement points across the city. Cross-Border Health Support: The MOP700 medical e-voucher scheme is set to keep the same value for 2026 and expand use to eligible Guangdong clinics starting next month, with vouchers also usable via “Macao One Account.” Infectious Disease Watch: Macau confirmed its first imported malaria case of the year—an adult man returning from Nigeria—while authorities continue hospital monitoring. Big Pharma Deal (Regional Impact): Bristol Myers Squibb and Hengrui Pharma signed a collaboration worth up to $15.2B for 13 early-stage oncology, hematology, and immunology programs, with Hengrui leading early development. Clinical Progress: EyePoint reported a DSMC recommendation to keep its DURAVYU wet AMD Phase 3 trials on track, citing continued favorable safety.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result.
Perspectify News
